GoodRx (GDRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Definitive additional proxy materials filed regarding upcoming shareholder meeting.
Filing confirms no fee required for submission under current SEC rules.
Voting matters and shareholder proposals
Proxy materials relate to matters requiring shareholder voting as per SEC regulations.
Shareholder rights and capital structure
Filing made under Schedule 14A, ensuring shareholders are informed and able to exercise voting rights.
Partial view of Summaries dataset, powered by Quartr API
Latest events from GoodRx
- 2024 revenue rose 6% to $792.3M with 32.8% margin; 2025 guidance targets further profitable growth.GDRX
Q4 20249 Jul 2026 - Pharma Direct surged 82% in Q1 2026, offsetting declines in other segments and raising guidance.GDRXQ1 20268 Jul 2026
- Q1 2025 revenue up 3%, net income positive, and margins strong amid strategic growth and guidance.GDRXQ1 20258 Jul 2026
- Direct contracting and scalable solutions drive growth and margin expansion amid industry shifts.GDRXUBS Global Healthcare Conference 20248 Jul 2026
- Direct contracting, ISP growth, and pharma solutions drive resilience amid retail volatility.GDRXCiti's 2024 Global Healthcare Conference8 Jul 2026
- Q3 2024 revenue up 8%, net income $4.0M, margin gains, and Pharma Solutions growth offset headwinds.GDRXQ3 20248 Jul 2026
- All proposals passed, with directors elected and no shareholder questions submitted.GDRXAGM 202616 Jun 2026
- Board recommends approval of all proposals at the virtual 2026 Annual Meeting.GDRXProxy filing29 Apr 2026
- Sharpened strategy and robust growth in integrated savings and pharma solutions drive margin gains.GDRXMorgan Stanley 22nd Annual Global Healthcare Conference5 Apr 2026